AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A pharmaceutical composition for ~~the treatment of~~ treating hypoptyalism, comprising pilocarpine, a bioadhesive polymer, a buffer, a lubricant, a softening agent, a hydrophilic substance and a hygroscopic substrate, combined in the form of a tablet, wherein the tablet dissolves when placed sublingually in the mouth of a subject and said composition adheres to the mucous tissues in the buccopharyngeal cavity, the pilocarpine then dissolving and binding to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, the pilocarpine then being absorbed by the cells and stimulating said glands to produce saliva

~~combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity~~.

2. (previously presented) The pharmaceutical composition according to claim 1, wherein the pilocarpine is the basic pilocarpine or pilocarpine in the form of salt, chlorohydrate or nitrate.

3. (previously presented) The pharmaceutical composition according to claim 1, wherein the composition is further combined with a mass substrate of the family of soluble carbohydrates with a low molecular weight, glucose or lactose.

4-8. (canceled)

9. (previously presented) A sublingual tablet for the treatment of hypoptyalism, comprising the pharmaceutical composition according to claim 1.

10. (previously presented) The sublingual tablet according to claim 9, wherein the bioadhesive polymer is selected from the group consisting of: cellulose derivatives, gums or polymers of the alginic acid type and derivatives, carboxy-vinyl polymer, carbomer, macrogols, gelatin, povidone, and pectins.

11. (previously presented) The sublingual tablet according to claim 9, wherein the tablet comprises:

2.5 mg pilocarpine that is basic or in salt form,
10.0 mg magnesium stearate,
90.0 mg sodium or disodium hydrogen phosphate,
50.0 mg K 100 methocel,
40.0 mg polyethylene glycol, 6000
20.0 mg hyaluronic acid,
15.0 mg lysozyme, and
772.5 mg compressed sorbitol qsp for 1000 mg.

12. (previously presented) The sublingual tablet according to claim 11, wherein the sodium or disodium hydrogen phosphate is replaced by sodium carbonate or sodium bicarbonate in the same proportions.

13-19. (canceled)

20. (previously presented) The sublingual tablet according to claim 10, wherein the tablet comprises:

2.5 mg pilocarpine that is basic or in salt form,
10.0 mg magnesium stearate,
90.0 mg sodium or disodium hydrogen phosphate,
50.0 mg K 100 methocel,
40.0 mg polyethylene glycol 6000,
20.0 mg hyaluronic acid,
15.0 mg lysozyme, and
772.5 mg compressed sorbitol qsp for 1000 mg.

21. (new) The pharmaceutical composition according to claim 1, comprising 0.20-2.5% by weight pilocarpine.

22. (new) The pharmaceutical composition according to claim 1, comprising 0.20-0.25% by weight pilocarpine.

23. (new) The pharmaceutical composition according to claim 1, further comprising 0.05-0.30% by weight lysozyme.

24. (new) The pharmaceutical composition according to claim 1, comprising pilocarpine in salt form, methylcellulose, sodium or disodium hydrogen phosphate, magnesium stearate, hyaluronic acid, polyethylene glycol, and sorbitol.